Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1994 1
2000 1
2002 2
2003 1
2005 2
2006 1
2007 1
2008 2
2009 1
2010 3
2011 1
2012 3
2013 7
2014 10
2015 10
2016 7
2017 6
2018 12
2019 14
2020 15
2021 16
2022 15
2023 15
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Staging of Bladder Cancer.
Ahmadi H, Duddalwar V, Daneshmand S. Ahmadi H, et al. Hematol Oncol Clin North Am. 2021 Jun;35(3):531-541. doi: 10.1016/j.hoc.2021.02.004. Epub 2021 Apr 15. Hematol Oncol Clin North Am. 2021. PMID: 33958149 Review.
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S. Powles T, et al. Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16. Nature. 2021. PMID: 34135506 Clinical Trial.
Transplantation Outcomes with Donor Hearts after Circulatory Death.
Schroder JN, Patel CB, DeVore AD, Bryner BS, Casalinova S, Shah A, Smith JW, Fiedler AG, Daneshmand M, Silvestry S, Geirsson A, Pretorius V, Joyce DL, Um JY, Esmailian F, Takeda K, Mudy K, Shudo Y, Salerno CT, Pham SM, Goldstein DJ, Philpott J, Dunning J, Lozonschi L, Couper GS, Mallidi HR, Givertz MM, Pham DT, Shaffer AW, Kai M, Quader MA, Absi T, Attia TS, Shukrallah B, Sun BC, Farr M, Mehra MR, Madsen JC, Milano CA, D'Alessandro DA. Schroder JN, et al. N Engl J Med. 2023 Jun 8;388(23):2121-2131. doi: 10.1056/NEJMoa2212438. N Engl J Med. 2023. PMID: 37285526 Clinical Trial.
Concomitant Tricuspid Repair in Patients with Degenerative Mitral Regurgitation.
Gammie JS, Chu MWA, Falk V, Overbey JR, Moskowitz AJ, Gillinov M, Mack MJ, Voisine P, Krane M, Yerokun B, Bowdish ME, Conradi L, Bolling SF, Miller MA, Taddei-Peters WC, Jeffries NO, Parides MK, Weisel R, Jessup M, Rose EA, Mullen JC, Raymond S, Moquete EG, O'Sullivan K, Marks ME, Iribarne A, Beyersdorf F, Borger MA, Geirsson A, Bagiella E, Hung J, Gelijns AC, O'Gara PT, Ailawadi G; CTSN Investigators. Gammie JS, et al. N Engl J Med. 2022 Jan 27;386(4):327-339. doi: 10.1056/NEJMoa2115961. Epub 2021 Nov 13. N Engl J Med. 2022. PMID: 34767705 Free PMC article. Clinical Trial.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial.
Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, Daneshmand S, Nishiyama H, Majchrowicz M, Degaonkar V, Shi Y, Mariathasan S, Grivas P, Drakaki A, O'Donnell PH, Rosenberg JE, Geynisman DM, Petrylak DP, Hoffman-Censits J, Bedke J, Kalebasty AR, Zakharia Y, van der Heijden MS, Sternberg CN, Davarpanah NN, Powles T; IMvigor010 Study Group. Bellmunt J, et al. Lancet Oncol. 2021 Apr;22(4):525-537. doi: 10.1016/S1470-2045(21)00004-8. Epub 2021 Mar 12. Lancet Oncol. 2021. PMID: 33721560 Free PMC article. Clinical Trial.
Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial.
Galsky MD, Daneshmand S, Izadmehr S, Gonzalez-Kozlova E, Chan KG, Lewis S, Achkar BE, Dorff TB, Cetnar JP, Neil BO, D'Souza A, Mamtani R, Kyriakopoulos C, Jun T, Gogerly-Moragoda M, Brody R, Xie H, Nie K, Kelly G, Horowitz A, Kinoshita Y, Ellis E, Nose Y, Ioannou G, Cabal R, Del Valle DM, Haines GK, Wang L, Mouw KW, Samstein RM, Mehrazin R, Bhardwaj N, Yu M, Zhao Q, Kim-Schulze S, Sebra R, Zhu J, Gnjatic S, Sfakianos J, Pal SK. Galsky MD, et al. Nat Med. 2023 Nov;29(11):2825-2834. doi: 10.1038/s41591-023-02568-1. Epub 2023 Oct 2. Nat Med. 2023. PMID: 37783966 Free PMC article. Clinical Trial.
Re: Incidence, Characteristics and Implications of Thromboembolic Events in Patients with Muscle Invasive Urothelial Carcinoma of the Bladder Undergoing Neoadjuvant Chemotherapy: W. C. Duivenvoorden, S. Daneshmand, D. Canter, Y. Lotan, P. C. Black, H. Abdi, B. W. van Rhijn, E. E. Fransen van de Putte, P. Zareba, I. Koskinen, W. Kassouf, S. L. Traboulsi, J. E. Kukreja, P. J. Bostrom, B. Shayegan and J. H. Pinthus J Urol 2016;196:1627-1633.
Ramos JD, Yu EY. Ramos JD, et al. J Urol. 2017 May;197(5):1360-1362. doi: 10.1016/j.juro.2016.12.094. Epub 2017 Feb 7. J Urol. 2017. PMID: 28183523 No abstract available.
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695).
Flaig TW, Tangen CM, Daneshmand S, Alva AS, Lucia MS, McConkey DJ, Theodorescu D, Goldkorn A, Milowsky MI, Bangs R, MacVicar GR, Bastos BR, Fowles JS, Gustafson DL, Plets M, Thompson IM Jr, Lerner SP. Flaig TW, et al. Eur Urol. 2023 Sep;84(3):341-347. doi: 10.1016/j.eururo.2023.06.014. Epub 2023 Jul 4. Eur Urol. 2023. PMID: 37414705 Clinical Trial.
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314.
Lu YT, Plets M, Morrison G, Cunha AT, Cen SY, Rhie SK, Siegmund KD, Daneshmand S, Quinn DI, Meeks JJ, Lerner SP, Petrylak DP, McConkey D, Flaig TW, Thompson IM Jr, Goldkorn A. Lu YT, et al. Eur Urol Oncol. 2023 Oct;6(5):516-524. doi: 10.1016/j.euo.2023.03.008. Epub 2023 Apr 20. Eur Urol Oncol. 2023. PMID: 37087309 Clinical Trial.
125 results